Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922035 · ClinicalTrials.gov registry record · Phase 1
CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant
A Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT03922035 is a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 36 participants, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03922035, a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot trial studies the side effects and how well CBM588 works in improving clinical outcomes in patients who have undergone donor hematopoietic stem cell transplant. Gut microbiota (formerly called gut flora) is the name given to the microbe (bacteria) population living in the intestine. Gut bacteria help the body to digest certain foods that the stomach and small intestine have not been able to digest. CBM588, may increase gut bacteria biodiversity, prevent recurrent symptoms of gastrointestinal toxicity (ranging from diarrhea to life-threatening inflammation of the colon).
Conditions Studied
Interventions
- OTHER Best Practice
- DRUG Clostridium butyricum CBM 588 Probiotic Strain
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-04-18 |
| Est. Completion | 2026-03-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03922035
The ClinicalTrials.gov registry entry for NCT03922035 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (96% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Best Practice is the first listed.
NCT03922035 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03922035 about?
NCT03922035 is a clinical study titled "CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant". This pilot trial studies the side effects and how well CBM588 works in improving clinical outcomes in patients who have undergone donor hematopoietic stem cell transplant. Gut microbiota (formerly called gut flora) is the name given to the microbe (bacteria) population living in the intestine. Gut b...
What is the current status of trial NCT03922035?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2019-04-18. Estimated completion is 2026-03-04.
What conditions does trial NCT03922035 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm.
What interventions are being tested in trial NCT03922035?
The interventions under investigation include: Best Practice (OTHER), Clostridium butyricum CBM 588 Probiotic Strain (DRUG).
Who is sponsoring clinical trial NCT03922035?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03922035 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphoid Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
RECRUITING · Phase 1
-
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
RECRUITING · Phase 1
-
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
RECRUITING · Phase 1
-
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
RECRUITING · Phase 1
-
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.